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S U M M A R Y
Objectives: A primary dose of the European Union (EU)-licensed meningococcal A, C, W-135, and Y
tetanus toxoid conjugate vaccine (MenACWY-TT) was immunogenic and well-tolerated in subjects aged
15–19 years. This study assessed antibody persistence at 3.5 years after vaccination with a MenACWY-TT
or a tetravalent ACWY polysaccharide vaccine (MenPS, control).
Methods: In the original study, participants were randomized to receive a single dose of MenACWY-TT or
MenPS. Serum bactericidal activity using rabbit serum as exogenous complement source was evaluated
up to 42 months post-vaccination.
Results: At 42 months post-vaccination with MenACWY-TT (n = 19) or MenPS (n = 17), all subjects in
each group had serum bactericidal activity titers 1:8 against all serogroups, except for two subjects
in the MenPS group against serogroup C. Geometric mean antibody titers were higher than pre-
vaccination levels at all post-vaccination time-points in both groups, and were signiﬁcantly higher in the
MenACWY-TT group versus the MenPS group for serogroup W-135 at month 42 (exploratory analysis).
Conclusions: These results indicate that seroprotection following primary vaccination with MenACWY-
TT extends more than 3 years. Ongoing persistence data are required to understand the duration of
protection following vaccination and to guide decisions on the need for future booster doses.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. 
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 1. Introduction
Invasive disease caused by Neisseria meningitidis remains an
important cause of death and disability in all age groups, but
particularly in children and adolescents for whom incidence rates
are highest.1,2 In industrialized countries, meningococcal ser-
ogroup B is an important cause of endemic invasive disease in all
age groups,1,2 but to date no broadly protective serogroup B
vaccine is available globally. After serogroup B, serogroup C (and
serogroup Y in the USA and some parts of Europe, namely
Scandinavia and Slovenia) causes most invasive disease in
industrialized countries.1–3 Serogroup A causes epidemic menin-
gococcal disease in Asia and Africa,3 while serogroup W-135 and
serogroup X are increasingly the causes of outbreaks in the Middle
East and Africa.3 Polysaccharide–protein conjugate vaccines
targeting meningococcal serogroup C have successfully controlled
serogroup C disease in countries where their widespread use has§ This study has been registered at www.clinicaltrials.gov NCT00390143.
* Corresponding author. Tel.: +45 8949 8300; fax: +45 8949 8310.
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http://dx.doi.org/10.1016/j.ijid.2012.10.001been implemented.4–6 Recent data from an interim analysis also
suggest good effectiveness of a USA-licensed tetravalent ser-
ogroups A, C, W-135, and Y diphtheria toxoid conjugate vaccine
(MenACWY-DT) against additional serogroups in the ﬁrst few
years post-vaccination.7
Meningococcal serogroup C vaccines have been shown to
induce a T-cell-dependant immune response that results in good
immunogenicity in infants and induction of B memory cells with
immune memory following later exposure.8 However, the
investigation of children who developed invasive meningococcal
disease after meningococcal serogroup C vaccination (i.e., vaccine
failures) showed that invasive disease occurred despite develop-
ment of a normal anamnestic response post-vaccination.9 Thus,
circulating antibody may be more important than anamnestic
responses in providing protection against invasive meningococcal
disease.9 This makes the long-term study of antibody persistence
after vaccination with meningococcal conjugate vaccines impor-
tant for understanding the duration of protection and for planning
future booster doses.
Tetravalent ACWY conjugate vaccines have been used for
vaccination of adolescents in the USA since 2005.10 Early
investigations have shown waning protective efﬁcacy ofLtd.  Open access under CC BY-NC-ND license. 
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waning immunity and concerns about the potential for vaccine
failures in the USA led to additional recommendations for a booster
dose 5 years after initial vaccination.11,12
This study was a 3.5-year serological follow-up of adolescents
previously vaccinated in a dose-ﬁnding study with a new
tetravalent meningococcal serogroups A, C, W-135, and Y tetanus
toxoid conjugate vaccine (NimenrixTM, GlaxoSmithKline Biologicals
SA; MenACWY-TT), recently approved by the European Medicines
Agency for individuals aged 12 months and above, or with a
tetravalent meningococcal ACWY polysaccharide vaccine (Mence-
vaxTM, GlaxoSmithKline Biologicals SA; MenPS, control).13
2. Materials and methods
This phase II, open study of antibody persistence was conducted
at a single center in Denmark between February 20, 2007 and May
5, 2009 (NCT00390143). The study objectives were to evaluate the
persistence of bactericidal antibodies 3.5 years (42 months) after
vaccination for each vaccine meningococcal serogroup, and to
assess serious adverse events related to vaccination and any
invasive meningococcal disease that occurred after the original
vaccination study.
The study was conducted in accordance with Good Clinical
Practice and the Declaration of Helsinki. The protocol and
associated documents were approved by the appropriate local
ethics committee. Written informed consent was obtained from
each subject or their parents/guardian, as appropriate, prior to the
performance of any study-speciﬁc procedures.
Subjects who had previously been randomized to receive
MenACWY-TT (5 mg each of serogroups A, C, W-135, and Y
capsular polysaccharide conjugated to tetanus toxoid, with A and C
polysaccharides conjugated to tetanus toxoid with a spacer
molecule) or to receive MenPS in the previous vaccination study
(NCT00126945),13 were invited to participate in the persistence
study. Subjects were not eligible if they had received any
meningococcal vaccine since the original study.
2.1. Immunogenicity assessment
Blood samples were collected before and 1 month after
vaccination, and from participants who returned at 18, 30, and/
or 42 months after vaccination.
Sera were tested for serum bactericidal activity (SBA) antibody
dilution titers using an assay with rabbit serum as exogenous
complement source (rSBA).14 The assay cut-off was a 1:8 dilution,
which was considered indicative of seroprotection for each
serogroup.15,16 The percentage of subjects reaching the more
conservative 1:128 threshold was also assessed. Meningococcal
strains used in the rSBA assays for serogroups C and Y were strain
C11 and strain S-1975, respectively. Strains used in the rSBA assay
for serogroups A and W-135 changed over the course of the study.
To allow comparability between time-points, sera were re-tested
post-hoc using assays developed with the new strains: an L10
immunotype strain for rSBA-MenA (previously an L11 strain17) and
strain MP01240070 for rSBA-MenW-135 (previously strain
319318). Inadequate volumes of sera collected at month 18 meant
that samples from this time-point could not be assessed using the
new strains. Therefore only results for serogroups C and Y are
reported for month 18.
2.2. Serious adverse events and invasive meningococcal disease
At each visit, the occurrence of serious adverse events related to
vaccination and the occurrence of invasive meningococcal disease
were retrospectively recorded.2.3. Statistical analyses
The analysis of immunogenicity was done on the according-to-
protocol (ATP) cohort for immunogenicity for the pre-vaccination
and month 1 post-vaccination time-points (see Østergaard et al.13
for a description of the ATP cohort for immunogenicity), and on the
ATP cohorts for persistence at each follow-up time-point. The ATP
persistence cohorts included all vaccinated subjects who attended
the follow-up visit, who complied with protocol procedures
speciﬁed in the vaccination and all previous follow-up phases,
who had the persistence visit according to the protocol-speciﬁed
time window, and for whom assay results for at least one tested
antigen were available.
The primary endpoint for persistence at each time-point
analyzed was the percentage of subjects with rSBA antibody titers
1:8. For each serogroup the geometric mean titer (GMT) was also
calculated. GMT ratios (MenACWY-TT/MenPS) were calculated
using an analysis of covariance (ANCOVA) model which included
the vaccine group as ﬁxed effect and the log-transformed pre-
vaccination titer from study NCT00126945 as the regressor. For the
comparison of percentages, the two vaccine groups were consid-
ered signiﬁcantly different if the standardized asymptotic 95%
conﬁdence interval (95% CI; MenACWY-TT minus MenPS) did not
contain the value 0. For GMTs the two vaccine groups were
considered signiﬁcantly different if the 95% CI for the GMT ratio
between the two vaccine groups did not contain the value 1.
Because these comparisons were exploratory (i.e., there was no
adjustment for multiplicity of endpoints and no pre-speciﬁed
deﬁnition of clinically-relevant differences), statistical differences
should be interpreted with caution.
The sample size was determined by the primary vaccination
study, as no new subjects were enrolled at any persistence time-
point. With 23 evaluable subjects in one group, the lower limit of
the asymptotic 95% CI on the percentage of subjects with rSBA titer
1:8 for one serogroup was 85%, assuming a true rate of 98%.
Analyses were performed using SAS software versions 8.2, 9.1,
or 9.2 (SAS Institute Inc., Cary, NC, USA) and ProcStatXact 5.0, 7.1,
or 8.1, for the month 18, 30, and 42 assessments, respectively.
3. Results
Fifty subjects were vaccinated with MenACWY-TT or MenPS in
the vaccination phase and were eligible to participate in the
persistence phase. Demographic characteristics were similar
between the two groups at each time-point (Table 1). There was
a higher proportion of female as compared to male subjects in both
treatment groups throughout the study.
At each post-vaccination time-point all subjects had rSBA titers
1:8 against meningococcal serogroups A, W-135, and Y. For
serogroup C, all subjects in the ATP persistence cohort at each
follow-up time-point had rSBA titers 1:8 up until month 42, at
which time 100% (95% CI 82.4–100%) of subjects in the MenACWY-
TT group (19/19) retained titers 1:8 compared with 88.2% (95% CI
63.6–98.5%) in the MenPS group (15/17). By month 42, the
percentages of subjects in the MenACWY-TT group who retained
rSBA titers 1:128 were 100% (95% CI 80.5–100%) for serogroup A
(17/17), 100% (95% CI 82.4–100%) for W-135 (19/19), 94.7% (95% CI
74.0–99.9%) for Y (18/19), and 78.9% (95% CI 54.4–93.9%) for
serogroup C (15/19). rSBA GMTs remained higher than pre-
vaccination levels at all time-points post-vaccination for all four
vaccine serogroups in both groups (Figure 1).
Exploratory analyses did not detect any statistically signiﬁcant
differences between groups for any of the four meningococcal
serogroups in terms of the percentage of subjects reaching the 1:8
and 1:128 rSBA thresholds. Exploratory analyses indicated that the
rSBA GMT for serogroup W-135 was signiﬁcantly higher in the
Table 1
Summary of participants at each time-point post-vaccination and reasons for elimination from the according-to-protocol (ATP) cohort
Vaccination phase Month 18 Month 30 Month 42
MenACWY-TT MenPS MenACWY-TT MenPS MenACWY-TT MenPS MenACWY-TT MenPS
Number eligible 24 26 24 26 24 26 24 26
Lost to follow-up - - 1 2 2 5 2 5
Declined to participate - - 0 1 0 1 0 1
Total cohort 24 26 23 23 22 20 22 20
Eliminated, reason Aa 0 1 0 1 0 1 0 0
Eliminated, reason Ba 0 0 2 3 3 3 3 3
ATP cohort 24 25 21 19 19 16 19 17
Age, years, mean (SD) 17.1 (1.25) 17.2 (1.01) 18.4 (1.24) 18.5 (1.17) 19.3 (1.25) 19.5 (1.26) 20.3 (1.24) 20.5 (1.23)
Male, n (%) 10 (41.7) 8 (32) 9 (42.9) 6 (31.6) 8 (42.1) 5 (31.3) 7 (36.8) 5 (29.4)
Female, n (%) 14 (58.3) 17 (68) 12 (57.1) 13 (68.4) 11 (57.9) 11 (68.8) 12 (63.2) 12 (70.6)
White/Caucasian, n (%) 23 (95.8) 25 (100) 20 (95.2) 19 (100) 18 (94.7) 16 (100) 18 (94.7) 17 (100)
East/Southeast Asian, n (%) 1 (4.2) 0 (0) 1 (4.8) 0 (0) 1 (5.3) 0 (0) 1 (5.3) 0 (0)
SD, standard deviation; MenACWY-TT, meningococcal A, C, W-135, and Y tetanus toxoid conjugate vaccine; MenPS, tetravalent meningococcal ACWY polysaccharide vaccine.
a A = subject received tetanus vaccine during the vaccination study; B = subject was non-compliant with the blood sampling schedule.
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statistically signiﬁcant differences between groups were observed
at other time-points for the other serogroups.
3.1. Serious adverse events
No serious adverse events related to vaccination or cases of
invasive meningococcal disease were reported in either group
during the 42-month post-vaccination follow-up period.
4. Discussion
Five meningococcal serogroups whose distribution varies
worldwide cause the majority of invasive meningococcal disease
(serogroups A, B, C, W-135, and Y).3 Global travel constitutes an52.8
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Figure 1. Serum bactericidal antibody geometric mean titers (rSBA GMTs) over time. rS
cohort for immunogenicity (vaccination phase) and the ATP cohorts for persistence at mo
analysis). Diamonds = MenACWY-TT group; open squares = MenPS group. Vertical lines i
at month 18 as different strains were used in these assays (MenA L11 and MenW-135 31
MP, respectively).increasing threat due to the risk of strain importation leading to
localized outbreaks, as demonstrated in 2000 and 2001 after the
importation and spread of serogroup W-135 across regions of
Europe by travelers from the Hajj.19 Tetravalent ACWY conjugate
vaccines targeting multiple serogroups currently offer the broadest
protection against meningococcal disease.
Available persistence data after vaccination with licensed
tetravalent ACWY vaccines (MenACWY-DT, ACWY conjugated to
mutated non-toxic diphtheria toxin (MenACWY-CRM197)) show
decreasing percentages of subjects with SBA titers above protec-
tive thresholds over time.20,21 Only one of these studies provided
data using rSBA (human complement SBA assays used by other
studies precludes inter-study comparisons). Twenty-two months
after vaccination of adolescents with MenACWY-CRM197 the
percentage of subjects with rSBA titers 1:8 was between 72%158.6
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BA GMTs after vaccination of 15–19-year-olds with MenACWY-TT or MenPS (ATP
nths 18, 30, and 42). *Statistically signiﬁcant difference between groups (exploratory
ndicate 95% conﬁdence intervals. Data are not reported for serogroups A and W-135
93, respectively) compared with the other time-points (MenA L10 and MenW-135
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DT the percentage was 60% to 95%. By contrast, 42 months after
MenACWY-TT vaccination, all subjects continued to have rSBA
titers 1:8 against each serogroup, although it should be noted
that rSBA assays run in different laboratories are not directly
comparable, and only small numbers of subjects were assessed in
the present study. Persistence of rSBA with the MenACWY-TT and
MenPS vaccines was observed to be comparable at month 42,
except for a signiﬁcantly higher rSBA GMT noted for serogroup W-
135 in those vaccinated with MenACWY-TT (exploratory compari-
son). Antibodies are thought to persist 3–5 years after vaccination
with meningococcal polysaccharide vaccines,22 but may persist for
up to 10 years in adults.23 Thus it may be too soon to observe
possible differences between the MenACWY-TT and MenPS groups
in the present study. In order to determine if antibodies will persist
for longer after MenACWY-TT vaccination than after vaccination
with plain polysaccharide, antibody persistence studies of longer
duration and in larger cohorts are currently ongoing
(NCT00356369, NCT00427908, NCT00955682, NCT00974363,
NCT01266993, NCT00718666, NCT00715910).
In conclusion, 42 months after vaccination with MenACWY-TT
or MenPS, rSBA titers remained high, indicating good long-term
persistence induced by a single dose of MenACWY-TT in this age
group. Ongoing persistence data are required to understand the
duration of protection following vaccination and to guide decisions
on the need for booster doses.
Mencevax and Nimenrix are trademarks of the GlaxoSmithKline
group of companies.
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